ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung cancer

Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-Small Cell Lung Cancer

May 1, 2025

Extended sleeve lobectomy (ESL) is considered a lung-sparing alternative to pneumonectomy (PN) for centrally located non-small cell lung cancer (NSCLC) when standard sleeve lobectomy (SSL) is not feasible. This retrospective study analyzed 94 patients who received neoadjuvant immunochemotherapy followed by either PN, ESL, or SSL.

Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)

May 1, 2025

The recent CheckMate 816 trial indicated that neoadjuvant chemo-immunotherapy provided limited local control in stage II–III resectable non-small cell lung cancer (NSCLC).

Estimated Worldwide Variation and Trends in Incidence of Lung Cancer by Histological Subtype in 2022 and Over Time: A Population-Based Study

April 17, 2025

This article presents a comprehensive epidemiological analysis of lung cancer, focusing on subtype-specific patterns worldwide.

Tumour Spread Through Air Spaces Is a Determiner for Treatment of Clinical Stage I Non-Small Cell Lung Cancer: Thoracoscopic Segmentectomy vs Lobectomy

March 13, 2025

This study investigates the impact of tumor spread through air spaces (STAS) on surgical outcomes for early-stage non-small cell lung cancer (NSCLC). In a retrospective analysis of 785 patients, 19.2 percent were found to have STAS-positive NSCLC.

Lung Cancer Screening and USPSTF Recommendations

March 6, 2025

Lung cancer remains the leading cause of cancer-related deaths, and low-dose computed tomography screening can reduce mortality for high-risk individuals.

Pages

Submit Content